S&P 500   4,657.76 (+1.37%)
DOW   35,153.41 (+0.73%)
QQQ   398.86 (+1.96%)
AAPL   160.38 (+2.28%)
MSFT   338.00 (+2.52%)
FB   337.81 (+1.41%)
GOOGL   2,901.33 (+2.03%)
AMZN   3,575.86 (+2.03%)
TSLA   1,134.88 (+4.90%)
NVDA   329.68 (+4.65%)
BABA   131.98 (-1.03%)
NIO   40.16 (+0.43%)
CGC   11.03 (-5.65%)
AMD   159.03 (+2.73%)
GE   97.59 (-0.26%)
MU   84.83 (+1.69%)
T   23.89 (-1.36%)
F   19.71 (-0.20%)
DIS   145.13 (-2.01%)
ACB   6.43 (-5.30%)
AMC   36.48 (-3.06%)
PFE   53.69 (-0.57%)
BA   196.95 (-1.13%)
S&P 500   4,657.76 (+1.37%)
DOW   35,153.41 (+0.73%)
QQQ   398.86 (+1.96%)
AAPL   160.38 (+2.28%)
MSFT   338.00 (+2.52%)
FB   337.81 (+1.41%)
GOOGL   2,901.33 (+2.03%)
AMZN   3,575.86 (+2.03%)
TSLA   1,134.88 (+4.90%)
NVDA   329.68 (+4.65%)
BABA   131.98 (-1.03%)
NIO   40.16 (+0.43%)
CGC   11.03 (-5.65%)
AMD   159.03 (+2.73%)
GE   97.59 (-0.26%)
MU   84.83 (+1.69%)
T   23.89 (-1.36%)
F   19.71 (-0.20%)
DIS   145.13 (-2.01%)
ACB   6.43 (-5.30%)
AMC   36.48 (-3.06%)
PFE   53.69 (-0.57%)
BA   196.95 (-1.13%)
S&P 500   4,657.76 (+1.37%)
DOW   35,153.41 (+0.73%)
QQQ   398.86 (+1.96%)
AAPL   160.38 (+2.28%)
MSFT   338.00 (+2.52%)
FB   337.81 (+1.41%)
GOOGL   2,901.33 (+2.03%)
AMZN   3,575.86 (+2.03%)
TSLA   1,134.88 (+4.90%)
NVDA   329.68 (+4.65%)
BABA   131.98 (-1.03%)
NIO   40.16 (+0.43%)
CGC   11.03 (-5.65%)
AMD   159.03 (+2.73%)
GE   97.59 (-0.26%)
MU   84.83 (+1.69%)
T   23.89 (-1.36%)
F   19.71 (-0.20%)
DIS   145.13 (-2.01%)
ACB   6.43 (-5.30%)
AMC   36.48 (-3.06%)
PFE   53.69 (-0.57%)
BA   196.95 (-1.13%)
S&P 500   4,657.76 (+1.37%)
DOW   35,153.41 (+0.73%)
QQQ   398.86 (+1.96%)
AAPL   160.38 (+2.28%)
MSFT   338.00 (+2.52%)
FB   337.81 (+1.41%)
GOOGL   2,901.33 (+2.03%)
AMZN   3,575.86 (+2.03%)
TSLA   1,134.88 (+4.90%)
NVDA   329.68 (+4.65%)
BABA   131.98 (-1.03%)
NIO   40.16 (+0.43%)
CGC   11.03 (-5.65%)
AMD   159.03 (+2.73%)
GE   97.59 (-0.26%)
MU   84.83 (+1.69%)
T   23.89 (-1.36%)
F   19.71 (-0.20%)
DIS   145.13 (-2.01%)
ACB   6.43 (-5.30%)
AMC   36.48 (-3.06%)
PFE   53.69 (-0.57%)
BA   196.95 (-1.13%)
OTCMKTS:INTI

Inhibitor Therapeutics Stock Forecast, Price & News

$0.16
0.00 (0.00%)
(As of 11/24/2021)
Add
Compare
Today's Range
$0.16
$0.16
50-Day Range
$0.12
$0.19
52-Week Range
$0.02
$0.35
Volume
2,200 shs
Average Volume
24,897 shs
Market Capitalization
$59.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.37
30 days | 90 days | 365 days | Advanced Chart
Receive INTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Inhibitor Therapeutics logo

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. It focuses on SUBA-Itraconazole, a patented, oral formulation of Itraconazole, for treatment of prostate and lung cancers. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.

Headlines

TIGIT Inhibitor Clinical Trials Intelligence 2022
November 26, 2021 |  ca.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:INTI
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($0.02) per share

Profitability

Net Income
$-1.06 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
359,523,000
Market Cap
$59.92 million
Optionable
Not Optionable

Company Calendar

Today
11/29/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Inhibitor Therapeutics (OTCMKTS:INTI) Frequently Asked Questions

How has Inhibitor Therapeutics' stock been impacted by COVID-19?

Inhibitor Therapeutics' stock was trading at $0.0756 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INTI shares have increased by 110.3% and is now trading at $0.1590.
View which stocks have been most impacted by COVID-19
.

Who are Inhibitor Therapeutics' key executives?

Inhibitor Therapeutics' management team includes the following people:
  • Nicholas Jon Virca, President & Chief Executive Officer
  • Garrison J. Hasara, Chief Financial Officer, Secretary & Treasurer
  • Amy M. McCord, Vice President-Regulatory Affairs

What is Inhibitor Therapeutics' stock symbol?

Inhibitor Therapeutics trades on the OTCMKTS under the ticker symbol "INTI."

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inhibitor Therapeutics' stock price today?

One share of INTI stock can currently be purchased for approximately $0.16.

How much money does Inhibitor Therapeutics make?

Inhibitor Therapeutics has a market capitalization of $59.92 million.

How many employees does Inhibitor Therapeutics have?

Inhibitor Therapeutics employs 2 workers across the globe.

What is Inhibitor Therapeutics' official website?

The official website for Inhibitor Therapeutics is www.inhibitortx.com.

Where are Inhibitor Therapeutics' headquarters?

Inhibitor Therapeutics is headquartered at 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609.

How can I contact Inhibitor Therapeutics?

Inhibitor Therapeutics' mailing address is 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609. The company can be reached via phone at (888) 841-6811, via email at [email protected], or via fax at 813-527-0500.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.